Announcements Trials
Browse Landscape

Phase

Phase 1 46Phase 2 24Phase 3 7Phase 1/2 6Phase NA 1Phase 4 1

Status

Completed 3Active not recruiting 3Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1NIH 1NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 160Thoracic 151Gynecologic 150Gastrointestinal 64Genitourinary 16Head & Neck 14Tumor-Agnostic 7Dermatologic 5Sarcoma 4Other solid neoplasm 2Other 1Endocrine 1Classical hematology 1

Conditions

Neoplasms 3Neoplasms, Unknown Primary 2Carcinoma 2Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Paclitaxel × Tumor-Agnostic × Clear all
NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Hoffmann-La Roche

Phase 3 Active not recruiting
49 enrolled
Tumor-Agnostic

Neoplasms

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed
851 enrolled 25 charts
Tumor-Agnostic

Carcinoma

NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT00003558 2013-08-07

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

National Cancer Institute (NCI)

Phase 3 Unknown
140 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 3 Completed
198 enrolled 7 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡